The biopharma landscape is forever changing, and with it, a demand from both patients and investors for the rapid development and progression of drug products to market. Analytical testing is a crucial part of this process and must be carefully considered when striving for a speedy development timeline while maintaining safety for patients. Well-designed analytical testing of biologics is...
Resources
eBook – Addressing the complex demands of cell line development
How can Bora Biologics help to support your next biologics project? Having a robust Cell Line Development (CLD) strategy is the foundation of biologic production that can propel a project, helping to streamline production while mitigating risk. A tailored and optimized cell line can be instrumental in overcoming development and manufacturing challenges and achieving a competitive advantage in...
Customized solutions for biologics development: leveraging adaptive platforms to meet customer needs
The rapidly growing numbers of monoclonal antibodies (mAbs), fusion proteins and biosimilars produced by the pharma industry have greatly improved patient care and resulted in a proliferation of innovative treatment options. To date, there are over 100 biosimilars [1, 2], 162 mAbs [3] and over 11 fusion proteins [4] approved for therapeutic use. These new therapeutic proteins are often more...
22nd Annual Contracting & Outsourcing Conference
September 21-22, 2023
Hyatt Regency New Brunswick
Table 91